RPG Life Sciences Announces Leadership Transition and Q4 Performance

RPG Life Sciences Limited has confirmed the cessation of Yugal Sikri as Managing Director, effective April 30, 2025, marking the end of his tenure after more than six years of leadership. The company has appointed Ashok Nair as his successor, set to take over as Managing Director from May 1, 2025.  

 

Under Sikri’s leadership, RPG Life Sciences witnessed significant growth, including a fourfold increase in EBITDA and an eightfold rise in net profit. His tenure also saw the company achieve debt-free status, enabling modernization and expansion efforts across its manufacturing facilities.  

 

The company has reported strong financial results for the fourth quarter, with revenue from operations reaching 1.43 billion rupees and net profit standing at 1.17 billion rupees. This performance underscores RPG Life Sciences’ continued strength in the pharmaceutical sector.  

 

In addition to its financial results, the company has declared a final dividend of 20 rupees per share and a special dividend of 4 rupees per share. The special dividend is attributed to exceptional profit from the assignment of surplus land, reflecting the company’s strategic financial planning.  

 

Market analysts view these developments as a positive indicator of RPG Life Sciences’ stability and future growth prospects. The leadership transition, coupled with strong financial performance, positions the company for continued success in the pharmaceutical industry.  

 

Key updates:  

 

- Yugal Sikri steps down as Managing Director, Ashok Nair to assume the role from May 1, 2025  

- Company reports Q4 revenue of 1.43 billion rupees and net profit of 1.17 billion rupees  

- Final dividend of 20 rupees per share and special dividend of 4 rupees per share declared  

- Leadership transition follows a period of significant financial growth and modernization  

- Analysts anticipate continued stability and expansion in RPG Life Sciences’ operations  

 

Sources: MarketScreener, Express Pharma, BW Healthcare World